# Anocca

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/anocca

- Industry: Biotechnology
- Headquarters: Sodertalje, Sweden
- Website: www.anocca.com
- Total disclosed funding: $47M
- Latest round: Series B (Jul 22, 2021)
- Investors on record: 4

## About

Anocca AB, based in Sweden, focuses on developing innovative precision T-cell immunotherapies that utilize advanced biotechnologies to replicate T-cell biology for effective cancer treatment.Anocca AB is a biotechnology firm specializing in T-cell immunotherapy solutions. Founded in 2014,the company has received a total of USD 129.91 in across 4 rounds of funding, with the most recent funding round occurring on August 5, 2025. The company is led by Reagan Jarvis, who has a history of founding and managing innovative biotech ventures. Anocca AB has its headquarters in Sweden but does not have any publicly disclosed subsidiaries.Anocca AB specializes in developing advanced precision T-cell immunotherapies, leveraging novel biotechnologies to replicate T-cell biology in laboratory settings. Their core offerings include T-cell receptor engineered T-cell therapy (TCR-T), designed to target untreatable cancers by utilizing the inherent ability of T-cells to recognize disease targets within cancer cells. This innovative approach enables the identification of previously unexplored therapeutic targets, enhancing the potential for personalized cancer treatment. Anocca's technologies are aimed at research institutions, oncology hospitals, and biopharmaceutical companies seeking to advance cancer therapies, primarily within the European and North American markets.he company generates revenue through partnerships and collaborations with research institutions and healthcare providers, focusing on the development and commercialization of its TCR-T therapies. The business model involves collaborative agreements where clients fund research and development in exchange for access to proprietary technologies and therapies, as well as revenue from licensing arrangements and milestone payments as products progress through clinical trials.In Augsut 2025, Anocca AB raised  SEK 440 million in venture funding led by returning investor Mellby Gård AB, with participation from other returning investors Ramsbury Invest AMF Fonder and Nidoco. Individual and other unspecified investors also participated in the round. This funding will be utilized to accelerate the development of its drug candidates, including theVIDAR-1 gene-edited TCR-T cell therapies for treating pancreatic cancer.

## Funding rounds

- Series B, Jul 22, 2021, $47M — Swedbank Robur, Danske Bank, Ramsbury Invest, Nidoco

## Investors

- Swedbank Robur — Series B
- Danske Bank — Series B
- Ramsbury Invest — Series B
- Nidoco (https://capitalatlas.ai/funds/nidoco) — Series B